...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis
【24h】

A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis

机译：吉西他滨同时质子放疗用于局部晚期胰腺癌且无远处转移的I / II期研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: We conducted the study to assess the feasibility and efficacy of gemcitabine-concurrent proton radiotherapy (GPT) for locally advanced pancreatic cancer (LAPC). Materials and methods: Of all 50 patients who participated in the study, 5 patients with gastrointestinal (GI)-adjacent LAPC were enrolled in P-1 (50 Gy equivalent [GyE] in 25 fractions) and 5 patients with non-GI-adjacent LAPC in P-2 (70.2 GyE in 26 fractions), and 40 patients with LAPC regardless of GI-adjacency in P-3 (67.5 GyE in 25 fractions using the field-within-a-field technique). In every protocol, gemcitabine (800 mg/m 2/week for 3 weeks) was administered concurrently. Every patient received adjuvant chemotherapy including gemcitabine after GPT within the tolerable limit. Results: The median follow-up period was 12.5 months. The scheduled GPT was feasible for all except 6 patients (12%) due to acute hematologic or GI toxicities. Grade 3 or greater late gastric ulcer and hemorrhage were seen in 5 patients (10%) in P-2 and P-3. The one-year freedom from local-progression, progression-free, and overall survival rates were 81.7%, 64.3%, and 76.8%, respectively. Conclusion: GPT was feasible and showed high efficacy. Although the number of patients and the follow-up periods are insufficient, the clinical results seem very encouraging.
机译：目的：我们进行了这项研究，以评估吉西他滨并发质子放射治疗（GPT）对局部晚期胰腺癌（LAPC）的可行性和有效性。材料和方法：在所有参与研究的50位患者中，有5位胃肠道（GI）邻近的LAPC患者被纳入P-1（25分数为50 Gy当量[GyE]）和5位非GI邻近的患者LA-2在P-2中（70.2 GyE，分为26个分数），以及40例LAPC患者，而与P-3中的GI无关（在25分数中，采用场内技术的67.5 GyE）。在每个方案中，吉西他滨（800 mg / m 2 /周，共3周）同时给药。每位患者接受GPT后在容许范围内接受辅助化疗，包括吉西他滨。结果：中位随访期为12.5个月。由于急性血液学或胃肠道毒性，预定的GPT对除6例患者（12％）以外的所有患者均可行。 P-2和P-3的5例患者（10％）出现3级或更高级别的晚期胃溃疡和出血。一年无局部进展，无进展和总生存率分别为81.7％，64.3％和76.8％。结论：GPT是可行的，并具有较高的疗效。尽管患者人数和随访时间不足，但临床结果似乎令人鼓舞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号